(57 days)
Not Found
Not Found
No
The device description details a competitive binding immunoassay based on chemical reactions and colorimetric detection, with no mention of computational analysis, algorithms, or learning processes.
No.
The device is an immunoassay for detecting barbiturates in urine, used for screening purposes, not for treating or preventing a disease or condition.
No
Explanation: The device provides preliminary data suggesting the presence of Barbital in urine but states it is "not intended to monitor drug levels, but only to screen urines for the presence of Barbiturate and its metabolites." It explicitly states that results "should be confirmed by other methods," indicating it is a screening tool, not a definitive diagnostic device.
No
The device description clearly outlines a physical chromatographic absorbent device with immobilized antigens and antibodies, indicating it is a hardware-based immunoassay test strip, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states it's for the "determination of Barbiturate in urine." This involves testing a sample taken from the human body (urine) in vitro (outside the body) to provide information about a physiological state (presence of Barbiturate).
- Device Description: The description details a "chromatographic absorbent device" that analyzes the urine sample through a chemical reaction involving antibodies and antigens. This is a typical mechanism for many IVD tests.
- Performance Studies: The document describes performance studies comparing the device's results to other methods (GC/MS, Emit II) using human urine samples. This is a standard part of demonstrating the performance of an IVD.
- Reference Device(s): The mention of "Reference Device(s)" like Syva EMIT /200 II and Emit II, which are known IVD drug screening tests, further supports that this device falls into the same category.
The definition of an IVD generally includes devices intended for use in the examination of specimens derived from the human body to provide information for diagnostic, monitoring, or screening purposes. This device fits that description.
N/A
Intended Use / Indications for Use
Syntron’s QuikStrip One Step Barbiturate assay is a rapid, qualitative, competitive binding immunoassay for the determination of Barbiturate in urine at the cutoff level of 200 ng/ml. The test provides only preliminary data which should be confirmed by other methods such as gas chromatography/mass spectrophotometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated6. Syntron’s QuikStrip One Step Barbiturate Test is not intended to monitor drug levels, but only to screen urines for the presence of Barbiturate and its metabolites.
Product codes (comma separated list FDA assigned to the subject device)
DIS
Device Description
Syntron's QuikStrip One Step Barbiturate Test consists of a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a drug conjugate immobilized on a porous membrane support for the limited antibody sites. As the test sample flows up through the absorbent device. the labeled antibody-dye conjugate binds to the free drug in the specimen forming an antibody:antigen complex. This complex competes with immobilized antigen conjugate in the positive reaction zone and will not produce a magenta color band when the drug is above the detection level of 200 ng/ml. Unbound dye conjugate binds to the reagent in the control zone, producing a magenta color band, demonstrating that the reagents and device are functioning correctly.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
medical/forensic screening
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
In-house testing of Syntron's QuikStrip One Step Barbiturate Test yielded a relative sensitivity or agreement within positive samples of 1.000 and relative specificity or agreement within negative samples of 1.000 and an accuracy of 100% when tested against Syva EMIT® /200 II on samples documented to be positive by GC/MS. A clinical trial consisting of 307 samples was run and the combined data yielded a relative sensitivity of 100%, a relative specificity of 99.41% with an accuracy of 99.61% when compared to Emit II® run at 200 ng/ml. By non parametric testing the results are not significantly different from one another. QuikStrip yielded 2 false positives due to the presence of an adulterant "Clean Jane" (sodium dodecylsulfate [Tide]). All positive samples by either screening method were confirmed by GC/MS (200 neml). The testing performed by both the sponsor and the Clinical Trial site did find 2 false positives and no false negatives in the samples tested. The False Positive was due to the presence of "Clean Jane" (sodium dodecylsulfate [Tidel). GC/MS confirmed the presence of sodium dodecylsulfate [Tide].
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study Type: In-house testing, Clinical Trial
Sample Size: In-house (not specified but positive and negative samples), Clinical Trial (307 samples)
Standalone Performance:
- In-house testing: relative sensitivity 1.000, relative specificity 1.000, accuracy 100% when tested against Syva EMIT® /200 II on GC/MS confirmed positive samples.
- Clinical trial: relative sensitivity 100%, relative specificity 99.41%, accuracy 99.61% when compared to Emit II® run at 200 ng/ml.
Key Results:
- Non parametric testing showed results are not significantly different from one another.
- QuikStrip yielded 2 false positives due to the presence of "Clean Jane" (sodium dodecylsulfate [Tide]).
- No false negatives were found.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
In-house testing:
- Relative sensitivity (agreement within positive samples): 1.000
- Relative specificity (agreement within negative samples): 1.000
- Accuracy: 100%
Clinical trial:
- Relative sensitivity: 100%
- Relative specificity: 99.41%
- Accuracy: 99.61%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3150 Barbiturate test system.
(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510k Submission for
QuikStrip One Step Barbiturate Test
Syntron Bioresearch, Inc.
FEB | 2 |998 Page 25 of 68
Revision A 8/18/97 Printed on 12/12/97
SUMMARY OF SAFETY AND EFFECTIVENESS 8.
The sponsor, Syntron Bioresearch, Inc. (2774 Loker Ave. West, Carlsbad, California, 92008), has developed, manufactured, and tested under GMP/GLP guidelines a device for the qualitative testing of urine for the presence of Barbiturate and its metabolites in a screening format.
The trade name of the device is QuikStrip One Step Barbiturate Test having a designated common name of Barbiturate Test System and a classification as a Class II device per 21 CFR 9 862.3150. This device is intended for the medical/forensic screening of urine.
Syntron's QuikStrip One Step Barbiturate Test consists of a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a drug conjugate immobilized on a porous membrane support for the limited antibody sites. As the test sample flows up through the absorbent device. the labeled antibody-dye conjugate binds to the free drug in the specimen forming an antibody:antigen complex. This complex competes with immobilized antigen conjugate in the positive reaction zone and will not produce a magenta color band when the drug is above the detection level of 200 ng/ml. Unbound dye conjugate binds to the reagent in the control zone. producing a magenta color band, demonstrating that the reagents and device are functioning correctly.
In-house testing of Syntron's QuikStrip One Step Barbiturate Test yielded a relative sensitivity or agreement within positive samples of 1.000 and relative specificity or agreement within negative samples of 1.000 and an accuracy of 100% when tested against Syva EMIT® /200 II on samples documented to be positive by GC/MS. A clinical trial consisting of 307 samples was run and the combined data vielded a relative sensitivity of 100%, a relative specificity of 99.41% with an accuracy of 99.61% when compared to Emit II® run at 200 ng/ml. By non parametric testing the results are not significantly different from one another. QuikStrip vielded 2 false positives due to the presence of an adulterant "Clean Jane" (sodium dodecylsulfate [Tide]).
All positive samples by either screening method were confirmed by GC/MS (200 neml) . The testing performed by both the sponsor and the Clinical Trial site did find 2 false positives and no false negatives in the samples tested. The False Positive was due to the presence of "Clean Jane" (sodium dodecylsulfate (Tidel). GC/MS confirmed the presence of sodium dodecylsulfate [Tide].
Additional information on this submission may be obtained by contacting Dr. Cleve W. Laird. President. Drial Consultants. Inc. at 805-522-6223(Ca) or by fax at 805-522-1526.
Proprietary Information Confidential
Do Not Copy
Proprietary Information Confidential
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of a human figure, represented by three curved lines that suggest a head, body, and legs.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
FEB 1 2 1998
Cleve W. Laird, Ph.D. President and CEO Drial Consultants, Inc. 1420 Los Angeles Avenue, Suite 201 Simi Valley, California 93065
K974712 Re: QuikStrip One Step Barbiturate Test Regulatory Class: II Product Code: DIS December 15, 1997 Dated: December 16, 1997 Received:
Dear Dr. Laird:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note:
this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Sitman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if Known): To be Assigned
Device Name: QuikStrip One Step Barbiturate Test
Indications For Use:
Syntron's QuikStrip One Step Barbiturate assay is a rapid, qualitative, competitive binding immunoassay for the determination of Barbiturate in urine at the cutoff level of 200 ng/ml. The test provides only preliminary data which should be confirmed by other methods such as gas chromatography/mass spectrophotometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated6. Syntron's QuikStrip One Step Barbiturate Test is not intended to monitor drug levels, but only to screen urines for the presence of Barbiturate and its metabolites.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANDOTHER PAGE IF NEEDED)
Concurance of CDRH, Office of Device Evaluation (ODE)
or
Teuaiki for ae Montgomery
(Division Sign-Off)
Division of Clinical Laboratory Devices K974 510(k) Number .
Perscription Use:
(Per 21 CFR 801.109
Over The Counter Use: (Optional Format 1-2-96)